Dyne Therapeutics BLA accepted for review, IND cleared for DYNE-302
Dyne Therapeutics reports BLA for z-rostudirsen accepted by FDA with Priority Review. The company also cleared an IND for DYNE-302 in FSHD, extending its pipeline via the FORCE platform.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day